



Received on 30 August 2015; received in revised form, 26 September 2015; accepted, 19 October 2015; published 31 October 2015

EFFECT OF *COMMIPHORA MUKUL* IN CHRONIC OXAZOLONE INDUCED MOUSE DERMATITIS MODEL

Rajesh Sundar ¹, Stephen Francis ², Pankaj K. Hiradhar ³, Navin Rajesh ^{*2} and Shilpesh Devada ⁴

International Institute of Biotechnology and Toxicology ¹, Chennai - 601301, Tamil Nadu, India.

Orchid Chemicals & Pharmaceuticals Ltd. ², Chennai - 600034, Tamil Nadu, India.

Veer Narmad South Gujarat University ³, Surat - 395007, Gujarat India.

Veterinary officer ⁴, Surat - 395007, Gujarat, India.

Keywords:

Commiphora mukul, Dermatitis, interferon- γ , oxazolone, TNF α

Correspondence to Author:

Dr. Shilpesh Devada

Op: Bus station, Vadi Vistar,
Santrampur, Mahisagar - 389260,
Gujarat, India.

E-mail: shilpeshdevda@yahoo.com

ABSTRACT: Aim: The objective of this study was to evaluate the effect of *Commiphora mukul* on psoriasis. **Materials and Methods:** Six female Balb/C mice per group of which, the first three groups served as untreated, disease controls and standard (0.1% dexamethasone) respectively. Animals of groups 4, 5 and 6 were applied 0.5, 1 and 2% of the *C. mukul* extract on both the ears, respectively. Dermatitis was induced in mice by the application of oxazolone 1.5% (100 μ L in ethanol) to the abdominal region for six days. Starting seven days following sensitization, 20 μ L of oxazolone 1% in a mixture of acetone and olive oil (4:1) was applied to both sides of the mouse ear on days 7, 10, 13 and 16. For detailed time-course analysis of swelling ear reactions, ear thickness was measured before the sensitization phase (day 7) and after each elicitation on days 10, 13, 16 and 19. **Results:** *C. mukul* potently suppressed ear swelling at each time-point. The suppressive rates of *C. mukul* at concentrations of 0.5, 1 and 2% were 47.3, 55.4 and 62.2% on day 16, respectively as compared to the disease control. Microscopic examination revealed a relatively swollen ear in the disease model as compared to the control animals. Whereas condition was gradually improved in treated groups dose-dependently. **Conclusion:** The results suggest that *C. mukul* improves chronic inflammatory skin disorders.

INTRODUCTION: Psoriasis is a common, immune-mediated, multifactorial disease. It is characterized by its vast phenotypic diversity and genetic heterogeneity. Psoriasis has an unknown etiology affecting 1 to 3% of Caucasians ¹. The most frequently affected than other ethnic groups were the Caucasians ² the rationality behind these variations is unclear. However, it is likely that both genetic and environmental factors play a role.

Psoriasis Vulgaris, the most common form of psoriasis, is characteristic of sharply demarcated, red, and scaly symmetrical plaques on the elbows, knees or scalp ³. It is a chronic inflammatory disease of the skin characterized by epidermal hyperplasia, dermal angiogenesis, infiltration of activated T cells, and increased cytokine levels. T cell-mediated immunity ⁴⁻⁷ in which cytokines play an essential role is considered to be the key element in the disease process.

Corticosteroids, immunosuppressants and non-steroidal anti-inflammatory drugs that inhibit cyclooxygenase (COX)-2 are being used clinically for the treatment of psoriasis. Systemic therapies with drugs such as acitretin, methotrexate,

	<p>QUICK RESPONSE CODE</p> <p>DOI: 10.13040/IJPSR.0975-8232.IJP.2(10).509-13</p>
	<p>Article can be accessed online on: www.ijpjournal.com</p>
<p>DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.2(10).509-13</p>	

cyclosporine, hydroxyurea, and thioguanine revealed significant systemic toxicity that needed to be followed carefully. Dramatic skin atrophy is characteristic of corticosteroids upon repeated application on the dorsal skin of rats⁸⁻¹⁰.

Commiphora mukul is found to grow in the wilder parts of the Indian states, especially Rajasthan, Karnataka, Maharashtra, Gujarat, Assam as well in neighboring countries viz., Afghanistan, Baluchistan, Arabia, and northeast Africa in dry rocky areas¹¹⁻¹³. It has been used for nearly 3000 years in Ayurvedic medicine, mainly as a treatment for arthritis. However, no scientific evidence or publications are available to support *C. Mukul's* therapeutic effect towards psoriasis, though used traditionally throughout the world.

The study of the anti-psoriatic effect of *C. mukul* conducted in the oxazolone-induced mouse contact dermatitis model provides a rational scientific proof that the herb indeed has the potential to treat psoriasis.

MATERIALS AND METHODS:

Plant Material (Test Material): Commercially available ethanol extract of *Commiphora mukul* (Batch Number: CM/06001) was procured from Natural Remedies Private Ltd., Bangalore, India. It was stored in an air-tight container at room temperature.

Animals: The study was carried out by the Protocol N^o 07/IAEC-03/TOX/2005, approved by the Institutional Animal Ethics Committee (IAEC), Research & Development, Orchid Chemicals and Pharmaceuticals Limited, Chennai.

A total of 36 female Balb/C mice randomized into six groups consisting of six animals per group were used for the study. Group 1 animals were used as an untreated control, which did not undergo any sensitization or elicitation procedures and treatment during the study. Dermatitis was induced to the animals of groups 2 to 6 with oxazolone. Group 2 animals served as the disease control not receiving any treatment with the *C. mukul* extract. Group 3 animals were treated by ear application, with 0.1% dexamethasone. Animals of groups 4, 5 and 6 received 0.5, 1 and 2% of the *C. mukul* extract on both the ears, respectively. The dose volume was maintained at 20 μ L uniformly.

Sensitization and Elicitation (Challenge Application) Procedure: The animals were sensitized by applying 100 μ L of 1.5% oxazolone in ethanol to the abdominal region of the animals for six days. Seven days after sensitization, 20 μ L of 1% oxazolone in a mixture of acetone and olive oil (4:1) was applied to both sides of the mouse ear on days 7, 10, 13 and 16. Sensitization and elicitation (challenge) treatments were carried out to induce dermatitis in the animals.

Measurements: During the study, ear thickness was measured with digital Vernier Calipers (Mitutoyo, Japan) at various time points. Ear thickness was measured before the sensitization phase (Day 7) and after each elicitation on days 10, 13, 16 and 19 to evaluate swelling ear reactions.

Animals were euthanized, and mouse ears were excised, fixed in 10%-buffered formalin solution, embedded in paraffin, cut into 5 μ m sections and stained with hematoxylin-eosin, 72 hours after the last application of oxazolone, by standard methods. During the histopathological evaluation, after the microscopic fields were photographed, the epidermal thickness was measured as the distance from the bottom of the stratum corneum to the basement membrane in the interfollicular epidermis (Reynolds *et al.*, 1998).

Inhibition of ear swelling (%), ear weight and epidermal thickness were calculated according to the following equation:

$$\text{Inhibition (\%)} = \frac{\text{Scores of the disease model} - \text{Scores of standard (Animals treated with 0.1\% dexamethasone) and } C. \text{ mukul treated animals}}{\text{Scores of the disease model} - \text{untreated control}} \times 100$$

The statistical significance ($P \leq 0.05$) was determined using Student's *t*-test using the statistical software Graph Pad Prism 4. The data are represented as mean \pm standard deviation (SD).

RESULTS AND DISCUSSION: Topical administration of *C. mukul* in an oxazolone-induced dermatitis mouse model to the ear of the disease model group (Group 2) revealed erythema (reddening of the skin), edema and abrasion of the skin occasionally.

The positive agent (dexamethasone 0.1%) potently suppressed oxazolone-induced ear swelling ($P \leq 0.01$) at the rate of 76% on day 16 **Table 1**. It is widely recognized that the secretion of cytokines by keratinocytes in response to injury, particularly TNF- α and IL-1 α are key mediators of the cutaneous inflammatory response¹⁴⁻¹⁵. *C. mukul* at the concentrations of 0.5 and 1% potently suppressed ($P \leq 0.05$) ear swelling at each time-point **Table 2** whereas *C. mukul* at the concentration of 2% potently suppressed ($P \leq 0.01$) ear swelling at each time point **Table 2**. The rate of suppression by *C. mukul* 0.5, 1, and 2% were 47.3, 55.4% and 62.2% on day 16, respectively as compared to the disease control **Table 1**. *C. mukul* treatment has been shown to reduce cytokine-induced activation of some pro-inflammatory genes in endothelial

cells and macrophages, including vascular cell adhesion molecule-1, cyclooxygenase-2, and IL-6. Thus, the anti-inflammatory effects of *C. mukul* activation could occur at both the induction of TNF- α and IL-1 and the downstream effects of these cytokines on other cells in the skin¹⁶⁻¹⁷. Oxazolone treatment of sensitized animals produced a significant increase in ear weight ($P \leq 0.05$) as compared to normal control animals. A dose-dependent ($P < 0.05$ and $P < 0.01$) decrease in ear weight **Table 3** was observed. Topical treatment of *C. mukul* at 0.5, 1, and 2% reduced oxazolone-induced inflammation of ear weight by 42.2, 54 and 69.2% respectively, as compared to the disease control **Table 1**. Dexamethasone 0.1%, used as a reference drug, also exhibited inhibition (74.5%).

TABLE 1: EFFECT OF *C. MUKUL* AND DEXAMETHASONE ON THE INHIBITION OF THICKNESS, WEIGHT AND EPIDERMAL THICKNESS OF MOUSE-EAR INDUCED BY REPEATED APPLICATION OF OXAZOLONE

Parameters	Inhibition (%)			
	Dexamethasone	<i>C. mukul</i> (%)		
		0.5	1	2
Ear thickness	75.7	47.3	55.4	62.2
Ear weight	74.5	42.2	54.0	69.2
Epidermal thickness	77.0	16.0	43.3	65.5

TABLE 2: EFFECT OF *C. MUKUL* ON THE THICKNESS (MM) OF MOUSE-EAR INDUCED BY REPEATED APPLICATION OF OXAZOLONE

Group	Treatment	Days			
		7	10	13	16
1	Vehicle	0.31±0.03	0.31±0.03	0.32±0.03	0.32±0.02
2	Oxazolone	0.32±0.02	0.54±0.02	0.63±0.08	1.06±0.08
3	Dexamethasone	0.31±0.02	0.47±0.03	0.48±0.07	0.50±0.40**
4	<i>C. mukul</i> 0.5%	0.32±0.03	0.45±0.07	0.52±0.10	0.71±0.09*
5	<i>C. mukul</i> 1 %	0.31±0.02	0.44±0.04	0.51±0.07	0.65±0.08*
6	<i>C. mukul</i> 2 %	0.33±0.02	0.43±0.08	0.59±0.05	0.60±0.06**

* $p < 0.05$ or ** $p < 0.01$ significantly lower than disease control (oxazolone). Values are mean \pm SD

TABLE 3: EFFECT OF *C. MUKUL* ON THE CHANGE IN WEIGHT (G) AND EPIDERMAL THICKNESS (μ M) OF MOUSE-EAR INDUCED BY REPEATED APPLICATION OF OXAZOLONE

Parameters	Vehicle	Oxazolone	Dexamethasone	<i>C. mukul</i> (%)		
				0.5	1	2
Ear weight (g)	71.5±0.7	242±5.7	115±7.1**	170±14.1*	150±4.1*	124±2.8**
Epidermal thickness (μ m)	13.5±0.4	89.7±0.3	31.0±11.7**	77.5±10.8*	56.7±8.1*	39.8±7.4**

* $P < 0.05$ or ** $P < 0.01$ significantly lower than disease control (oxazolone). Values are mean \pm SD

Histopathological Evaluation and Measurement of Epidermal Thickness in the Ear:

Histopathological evaluation of mouse ear revealed prominent epidermal hyperplasia and marked infiltration of inflammatory cells **Fig. 1**, consisting of monocytes, granulocytes, and macrophages, mainly into the dermis and some into the epidermis. Microscopic examination showed a

relatively swollen ear in the disease model as compared to the control animals. The ear of the untreated control animals exhibited a thin epidermal layer. The severity of the epidermal hyperplasia was assessed by measuring the epidermal thickness induced by oxazolone application. Epidermal thickness **Table 3** was significantly increased in the disease model (two to

three folds) as compared to the untreated control. The epidermal thickness of animals treated with *C. mukul* at concentrations of 0.5, 1 and 2% revealed a significantly reduced epidermal thickness by 16.0,

43.3 and 65.5%, respectively **Table 3**, as compared to the untreated control animals. Animals treated with dexamethasone 0.1% decreased ear epidermal thickness by 77%.




FIG. 1: EFFECT OF *C. MUKUL* EXTRACT AND DEXAMETHASONE ON EAR EPIDERMAL THICKNESS OF MICE TREATED WITH OXAZOLONE. (A) Untreated control exhibit a thin epidermal layer; (B) A two to three-fold in the ear epidermal thickness in disease control as compared to the untreated control; (C) Decreased ear epidermal thickness in animals treated with dexamethasone (reference drug) at 0.5 %; (D, E, and F) Epidermal thickness of the disease induced animals treated with *C. mukul* at concentrations of 0.5, 1 and 2% revealing a significantly reduced epidermal thickness (16.0, 43.3 and 65.5%, respectively). Hematoxylin and eosin stained sections of skin. Magnification x 10.

CONCLUSION: The results obtained from the study suggest that *C. mukul* improves chronic inflammatory skin disorders probably through the inhibition of $TNF\alpha$ produced by macrophage cells and interferon- γ produced by the Th1 cells.

ACKNOWLEDGEMENT: Nil

CONFLICT OF INTEREST: Nil

REFERENCES:

1. Christophers E: Psoriasis – epidemiology and clinical spectrum. *Clin Exp Dermatol* 2001; 26(4): 314-320.
2. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T and Margolis DJ: The prevalence of psoriasis in African Americans: results from a population-based study. *J Am Acad Dermatol* 2005; 52(1): 23-26.
3. Lomholt G: Psoriasis: Prevalence, spontaneous course, and genetics: a census study on the prevalence of skin diseases on Faroe Islands, GEC Gad, Copenhagen. Lotus Natural Health and Healing Center (1999) Ayurveda bulk herbs 1963.
4. Barker JNWN: The pathophysiology of psoriasis. *Lancet*. 1991; 338(8761): 227-330.
5. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB and Krueger JG: The response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. *Nat Med* 1995; 1(5): 442-447.

6. Griffiths CE and Voorhees JJ: Psoriasis T cells and autoimmunity. *J R Soc Med* 1996; 89(6): 315-319.
7. Krueger J.G., The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol* 2002; 46(1): 1-23.
8. Schafer-Korting M, Schmid MH and Korting HC: Topical glucocorticoids with the improved risk-benefit ratio. The rationale of a new concept. *Drug Saf* 1996; 14(6): 375-385.
9. Reynolds NJ, Voorhees JJ and Fisher GJ: Cyclosporin A inhibits 12-0-tetradecanoyl-phorbol-13-acetate-induced cutaneous inflammation in severe combined immunodeficient mice that lack functional lymphocytes. *Br J Dermatol* 1998; 139(1): 16-22.
10. Sakumar S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T and Goto T: Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). *Int J Immunopharmacol* 2001; 1(6): 1219-1226.
11. Atal CK, Gupta OP and Afaq SH: *Commiphora mukul*: a source of gugal in Indian systems of medicine. *Econ Bot*, 1975; 29: 209-218.
12. Varier VPS: Indian Medicinal Plants. (<http://www.vedamsbooks.com/no9774.htm>) 1994.
13. Sabinsa 2000: *Commiphora mukul*: The plant source of Gugulipid®.
14. Piguet PF: TNF and the pathology of the skin. *Res Immunol*. 1993 144(5): 320-326.
15. Murphy JE, Robert C and Kupper TS: Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. *J Invest Dermatol* 2000; 114(3): 602-608.
16. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J and Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPAR-alpha but not by PPAR gamma activators. *Nature* 1998; 393(6687): 790-793.
17. Delerive P, De Bosscher K, Besnard S, Vanden BW, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G and Staels B: Peroxisome proliferator-activated receptor-alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. *J Biol Chem* 1999; 274(45): 32048-32054.

How to cite this article:

Sundar R, Francis S, Hiradhar PK, Rajesh N and Devada S: Effect of *Commiphora mukul* in chronic oxazolone induced mouse dermatitis model. *Int J Pharmacognosy* 2015; 2(10): 509-13. doi: 10.13040/IJPSR.0975-8232.2(10).509-13.

This Journal licensed under a Creative Commons Attribution-Non-commercial-Share Alike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)